Label: SODIUM SULFACETAMIDE AND SULFUR- sulfacetamide sodium, sulfur liquid
58657-472-12, view more58657-472-13
- Packager: Method Pharmaceuticals, LLC
- Category: HUMAN PRESCRIPTION DRUG LABEL
DISCLAIMER: This drug has not been found by FDA to be safe and effective, and this labeling has not been approved by FDA. For further information about unapproved drugs, click here.
Updated December 17, 2021
If you are a healthcare professional or from the pharmaceutical industry please visit this version.
- SPL UNCLASSIFIED SECTION
Each gram of sodium sulfacetamide 10% and sulfur 5% cleanser contains
100 mg of sodium sulfacetamide and 50 mg of sulfur in a cleanser
containing Aloe Vera leaf Extract, Butylated Hydroxytoluene, Cetyl Alcohol,
Citric Acid, Cocamidopropyl Betaine, Disodium EDTA, Glycerin, Glyceryl
Stearate SE, PEG-100 Stearate, Phenoxyethanol, Purified Water, Sodium
laureth sulfate, Sodium Thiosulfate, Stearyl alcohol, Triacetin, Xanthan Gum.
Sodium sulfacetamide is a sulfonamide with antibacterial activity while sulfur acts as a keratolytic agent. Sodium sulfacetamide is C 8H 9N 2NaO 3S·H2O with molecular weight of 254.24. Chemically, it is N-[(4-aminophenyl)sulfonyl]-acetamide, monosodium salt, monohydrate.
The structural formula is:
The most widely accepted mechanism of action of sulfonamides is the Woods-Fildes theory, which is based on the fact that sulfonamides act as competitive antagonists to para-aminobenzoic acid (PABA), an essential component for bacterial growth. While absorption through intact skin has not been determined, sodium sulfacetamide is readily absorbed from the gastrointestinal tract when taken orally and excreted in the urine, largely unchanged. The biological half-life has variously been reported as 7 to 12.8 hours.
The exact mode of action of sulfur in the treatment of acne is unknown, but it has been reported that it inhibits the growth of Propionibacterium acnes and the formation of free fatty acids.
Although rare, sensitivity to sodium sulfacetamide may occur. Therefore, caution and careful supervision should be observed when prescribing this drug for patients who may be prone to hypersensitivity to topical sulfonamides. Systemic toxic reactions such as agranulocytosis, acute hemolytic anemia, purpura hemorrhagica, drug fever, jaundice and contact dermatitis indicate hypersensitivity to sulfonamides. Particular caution should be employed if areas of denuded or abraded skin are involved.
Sulfonamides are known to cause Stevens-Johnson syndrome in hypersensitive individuals. Stevens-Johnson syndrome also has been reported following the use of sodium sulfacetamide topically. Cases of drug induced systemic lupus erythematosus from topical sulfacetamide also have been reported. In one of these cases, there was a fatal outcome. KEEP OUT OF REACH OF CHILDREN.
OTHER SAFETY INFORMATION
NOTICE: Protect from freezing and excessive heat. The product may tend to
darken slightly on storage. Slight discoloration does not impair the efficacy
or safety of the product. Keep bottle tightly closed.
Occasionally, a slight discoloration of fabric may occur when an excessive
amount of the product is used and comes in contact with white fabrics.
This discoloration, however, presents no problem, as it is readily removed
by ordinary laundering without bleaches.
DOSAGE AND ADMINISTRATION
USE: Wash affected area once or twice daily, or as
directed by your physician. Avoid contact with eyes or mucous membranes.
Wet skin and liberally apply to areas to be cleansed, massage gently into
skin for 10-20 seconds working into a full lather, rinse thoroughly and pat
dry. If drying occurs, it may be controlled by rinsing cleanser off sooner or
using less often. See label booklet for Full Prescribing Information.
FOR EXTERNAL USE ONLY. NOT FOR INTRAVAGINAL OR OPHTHALMIC
USE. (KEEP AWAY FROM EYES).
KEEP OUT OF REACH OF CHILDREN.
- Package Label
INGREDIENTS AND APPEARANCE
SODIUM SULFACETAMIDE AND SULFUR
sulfacetamide sodium, sulfur liquid
Product Information Product Type HUMAN PRESCRIPTION DRUG Item Code (Source) NDC:58657-472 Route of Administration TOPICAL Active Ingredient/Active Moiety Ingredient Name Basis of Strength Strength SULFACETAMIDE SODIUM (UNII: 4NRT660KJQ) (SULFACETAMIDE - UNII:4965G3J0F5) SULFACETAMIDE SODIUM 100 mg in 1 g SULFUR (UNII: 70FD1KFU70) (SULFUR - UNII:70FD1KFU70) SULFUR 50 mg in 1 g Inactive Ingredients Ingredient Name Strength BUTYLATED HYDROXYTOLUENE (UNII: 1P9D0Z171K) ALOE VERA LEAF (UNII: ZY81Z83H0X) 1-ETHYL CITRATE (UNII: Y7R23627P5) CETYL ALCOHOL (UNII: 936JST6JCN) EDETATE DISODIUM (UNII: 7FLD91C86K) GLYCERYL STEARATE SE (UNII: FCZ5MH785I) PEG-100 STEARATE (UNII: YD01N1999R) COCAMIDOPROPYL BETAINE (UNII: 5OCF3O11KX) TRIACETIN (UNII: XHX3C3X673) WATER (UNII: 059QF0KO0R) SODIUM THIOSULFATE (UNII: HX1032V43M) SODIUM LAURYL SULFATE (UNII: 368GB5141J) STEARYL ALCOHOL (UNII: 2KR89I4H1Y) XANTHAN GUM (UNII: TTV12P4NEE) GLYCERIN (UNII: PDC6A3C0OX) PHENOXYETHANOL (UNII: HIE492ZZ3T) Packaging # Item Code Package Description Marketing Start Date Marketing End Date 1 NDC:58657-472-06 170 g in 1 BOTTLE, PLASTIC; Type 0: Not a Combination Product 11/15/2021 2 NDC:58657-472-07 170.3 g in 1 BOTTLE, PLASTIC; Type 0: Not a Combination Product 11/15/2021 3 NDC:58657-472-12 340 g in 1 BOTTLE, PLASTIC; Type 0: Not a Combination Product 11/15/2021 4 NDC:58657-472-13 340.2 g in 1 BOTTLE, PLASTIC; Type 0: Not a Combination Product 11/15/2021 5 NDC:58657-472-08 227 g in 1 BOTTLE, PLASTIC; Type 0: Not a Combination Product 11/15/2021 Marketing Information Marketing Category Application Number or Monograph Citation Marketing Start Date Marketing End Date unapproved drug other 11/15/2021 Labeler - Method Pharmaceuticals, LLC (060216698)